The GLP-1s That Were Quietly Discontinued — and What They Tell You About the Ones Left

If you research GLP-1 medications, you will read about Byetta and Bydureon BCise as if you can walk into a pharmacy and fill them today. You can't. Both were discontinued in the United States in 2024, and the fact that so much published content still presents them as current options is a small but real hazard — it sends people asking for drugs their pharmacy can no longer order.

Here's the accurate version, and why the discontinuations are actually a useful lens on the drugs that remain.

What was discontinued, and when

• Byetta (exenatide) and Bydureon BCise (extended-release exenatide) were discontinued in the U.S. in October 2024.
• Saxenda (liraglutide for weight management) is next: Novo Nordisk has told the FDA it will be available until it is discontinued in January 2027.
• Victoza (liraglutide for type 2 diabetes) is often listed as discontinued in 2024. That was the UK. In the U.S. it is still sold, though the FDA drug shortage database lists it with limited availability.

These weren't safety recalls. They were commercial discontinuations — the manufacturers stopped making and selling them. That distinction matters: a recalled drug is pulled because something's wrong with it; a discontinued drug is simply no longer produced, usually because newer options captured the market and the older ones stopped making business sense.

Why the older GLP-1s lost

The discontinued drugs share a trait: they were harder to take, less effective, or both, compared with what replaced them.

• Byetta was twice-daily. In a category where the current standard is a once-weekly injection, a drug you inject twice a day is a hard sell no matter how well it works.
• Bydureon BCise was weekly, but its extended-release formulation was fiddly to prepare and inject compared with a modern pen.
• On raw effectiveness, the older exenatide products produced less weight loss and less glucose lowering than semaglutide and tirzepatide. When the newer molecules arrived with better results and less frequent dosing, the older ones had no lane left.

So the discontinuations tell you something real about the survivors: the drugs still on the market — semaglutide and tirzepatide — won on the two axes that decide these things, convenience and magnitude of effect. That's the same reason the head-to-head weight-loss numbers for the current drugs are so much larger than the older ones ever posted.

If a discontinued GLP-1 is still on your chart

Two situations come up:

You're still taking one. Some patients were stable on an exenatide product and worked through remaining supply, and people on Saxenda now face the same question before January 2027. If that's you, this is a prescriber conversation, not a stop-cold decision — the point is to plan a switch to a current agent, not to run out unexpectedly. Don't stop an antidiabetic medication on your own because you read it was discontinued; arrange the transition.

You're reading old advice. If an article, a forum post, or even a clinic handout is recommending Byetta or Bydureon BCise as a live option, treat the whole source as out of date. Content that hasn't been updated since early 2024 will be wrong about more than just which drugs exist — it'll be wrong about prices, shortages, and programs too. The GLP-1 landscape moved faster in 2024–2026 than almost any drug category, and undated content ages badly.

I keep a dated, regularly-checked news log of exactly these kinds of changes — discontinuations, approvals, shortage resolutions — here, specifically so that "is this still true?" has an answer with a date on it.

The one that wasn't discontinued — and why the distinction matters

Not every older GLP-1 left, and the two liraglutide brands show why you can't reason from molecule to availability. Victoza (liraglutide for type 2 diabetes) was discontinued in the UK in 2024 — the source of many reports that it was gone — but in the U.S. it is still sold, with limited supply. Saxenda (liraglutide for weight management) stayed on sale, and it is the one now being discontinued: Novo Nordisk has told the FDA it will be available until January 2027. Same molecule, opposite outcomes, decided brand by brand and country by country. If a specific product matters to you, check that exact brand in the U.S., not the molecule.

You can see the current status of the individual older brands — Byetta, Victoza, and Saxenda — laid out separately for this reason.

The takeaway

Two GLP-1 brands left the U.S. market in 2024 — Byetta and Bydureon BCise, in October — and Saxenda follows in January 2027. Byetta and Bydureon BCise were discontinued for commercial reasons, not safety ones, and they lost because the newer molecules were both easier to take and more effective. The practical lessons: if you're on one, plan a managed switch rather than an abrupt stop; and if a source is still recommending them in the present tense, that source is old enough that you shouldn't trust its other claims either. In this category, the date on the information is almost as important as the information.

Correction, September 16, 2026: an earlier version of this article said Victoza was discontinued in the U.S. in April 2024. That withdrawal was in the UK; in the U.S., Victoza is still sold. U.S. status re-read from FDA's NDC directory and drug shortage database on September 16, 2026. This is general information, not medical advice — never stop or switch a prescribed medication without your prescriber.